RenovoRx Inc (RNXT): Next-Year EPS Estimate 60.95%
As of 2026-11-12, RenovoRx Inc (RNXT) has a next-year EPS growth estimate of 60.95%. Featured in 4 EPS revision reports, most recently on 2026-09-04.
On 2026-11-10, analyst consensus for RNXT's next-year EPS growth shifted from 38.26% to 60.95% — a positive change of 22.69 percentage points. The revised estimate has been sustained across 3 subsequent trading sessions. Current-year growth is projected at 17.97%.
What's Driving This
RNXT’s rise is not explained by an EPS estimate upgrade in the provided data: the only revision shown lowered next-year EPS growth from 46.67% to 38.26% on 202
Generated 2026-11-09 from news as of 2026-11-09
Current Snapshot
- Sector
- Healthcare
- Industry
- Biotechnology
- EPS growth next year
- 60.95%
- EPS growth this year
- 17.97%
- EPS next quarter (est)
- -$0.06
- Last price
- $1.16
EPS Revision History
| Date | EPS Next Y | EPS This Y | Next Q (est) | Price |
|---|---|---|---|---|
| 2026-11-12 | 60.95% | 17.97% | -$0.06 | $1.16 |
| 2026-11-11 | 60.95% | 17.97% | -$0.06 | $1.22 |
| 2026-11-10 | 60.95% | 17.97% | -$0.06 | $1.18 |
| 2026-11-09 | 38.26% | 10.16% | -$0.07 | $1.18 |
| 2026-11-07 | 38.26% | 10.16% | -$0.07 | $1.13 |
| 2026-11-06 | 38.26% | 10.16% | -$0.07 | $1.13 |
| 2026-11-05 | 46.67% | 17.97% | -$0.06 | $1.19 |
| 2026-11-04 | 46.67% | 17.97% | -$0.06 | $1.31 |
| 2026-11-03 | 46.67% | 17.97% | -$0.06 | $1.29 |
| 2026-11-02 | 46.67% | 17.97% | -$0.06 | $1.26 |
| 2026-10-31 | 46.67% | 17.97% | -$0.06 | $1.33 |
| 2026-10-30 | 46.67% | 17.97% | -$0.06 | $1.33 |
| 2026-10-29 | 46.67% | 17.97% | -$0.06 | $1.49 |
| 2026-10-28 | 46.67% | 17.97% | -$0.06 | $1.42 |
| 2026-10-27 | 46.67% | 17.97% | -$0.06 | $1.39 |
| 2026-10-26 | 46.67% | 17.97% | -$0.06 | $1.31 |
| 2026-10-23 | 46.67% | 17.97% | -$0.06 | $1.29 |
| 2026-10-22 | 46.67% | 17.97% | -$0.06 | $1.27 |
| 2026-10-21 | 46.67% | 17.97% | -$0.06 | $1.23 |
| 2026-10-20 | 46.67% | 17.97% | -$0.06 | $1.20 |
| 2026-10-19 | 46.67% | 17.97% | -$0.06 | $1.16 |
| 2026-10-16 | 46.67% | 17.97% | -$0.06 | $1.14 |
| 2026-10-15 | 46.67% | 17.97% | -$0.06 | $1.19 |
| 2026-10-14 | 46.67% | 17.97% | -$0.06 | $1.12 |
| 2026-10-13 | 46.67% | 17.97% | -$0.06 | $1.15 |
| 2026-10-12 | 46.67% | 17.97% | -$0.06 | $1.25 |
| 2026-10-11 | 46.67% | 17.97% | -$0.06 | $1.28 |
| 2026-10-10 | 46.67% | 17.97% | -$0.06 | $1.28 |
| 2026-10-09 | 46.67% | 17.97% | -$0.06 | $1.28 |
| 2026-10-08 | 46.67% | 17.97% | -$0.06 | $1.33 |
Reports Featuring RNXT
Recent News
- RenovoRx Posts First $1 Million Quarter And Misses On EPS As Sequential Growth Slows And Q4 Targets Get HarderEarnings Whispers
- RenovoRx Reports Record Third Quarter 2026 Revenue Exceeding $1 MillionGlobeNewswire
- RenovoRx Secures First Notice of Allowance for Japanese Patent Covering its RenovoCath Device for Targeted, Local Drug-Delivery via the Vasa VasorumGlobeNewswire
- RenovoRx Inc (RNXT) Q4 2025 Earnings Call Highlights: Strong Revenue Growth and Strategic ...GuruFocus.com
- RenovoRx Reports Full Year 2025 Financial Results and Provides Business UpdateGlobeNewswire
- Earnings To Watch: RenovoRx Inc (RNXT) Reports Q1 2026 ResultGuruFocus.com
- RenovoRx Announces Key Phase III Milestone: TIGeR-PaC Trial Surpasses 100 Randomized Patients as Study Nears Completion of EnrollmentGlobeNewswire
Screen Performance
Aggregate stats across all 2145 tickers our top-EPS-revision screen has flagged over the past 225 days.
- Median return since detection
- -2.9%
- % of tickers in the green
- 43%
- Median return on winners
- +22.8%
- Large revisions captured
- 2246
Past detection performance reflects the price change between when a ticker first entered our screen and the most recent observation. Not a forward-looking forecast.
Also Tracked by Our Screen
Frequently Asked Questions
What is RenovoRx Inc's next-year EPS growth estimate?▾
As of 2026-11-12, RenovoRx Inc (RNXT) has a next-year EPS growth estimate of 60.95%, based on analyst consensus.
When was the latest EPS estimate revision for RNXT?▾
The most recent revision occurred on 2026-11-10, when analysts adjusted the next-year EPS growth estimate from 38.26% to 60.95%.
What sector and industry does RenovoRx Inc belong to?▾
RenovoRx Inc operates in the Healthcare sector, specifically the Biotechnology industry.
How often is this EPS estimate data updated?▾
EPS revision data is refreshed daily from analyst consensus estimates. RNXT appears on this page because it was flagged by our daily top-EPS-revision-performer screen.
EPS revision data sourced from analyst consensus estimates, refreshed daily. RenovoRx Inc (RNXT) appears here because it was detected by our daily top-EPS-revision-performer screen.